Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan

BMC Cardiovascular Disorders

Volumn 12, Issue , 2012, Pages

  De Haro, Joaquin ^a   Acin, Francisco ^a   Bleda, Silvia ^a   Varela, Cesar ^a   Esparza, Leticia ^a  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; ANTIHYPERTENSIVE AGENT; SULFONAMIDE;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD FLOW; BUERGER DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DIGITAL SUBTRACTION ANGIOGRAPHY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEMODYNAMICS; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; OUTCOME ASSESSMENT; PAIN; PERIPHERAL EDEMA; PILOT STUDY; PRIORITY JOURNAL; SIDE EFFECT; ULCER; AMPUTATION; LIMB; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADULT; AMPUTATION; ANTIHYPERTENSIVE AGENTS; EXTREMITIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; SULFONAMIDES; THROMBOANGIITIS OBLITERANS; TREATMENT OUTCOME;

EID: 84858406581     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-12-5     Document Type: Article

References (25)

1. Olin J, Young J, Graor R, Ruschhaupt W, Bartholomew J. The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease). Circulation 1990, 82(5 Suppl 4):3-8.
2. Yorukoglu Y, Ilgit E, Zengin M, Nazliel K, Salman E, Yucel E. Thromboangiitis obliterans (Buerger's disease in women-a reevaluation). Angiology 1993, 44:527-532. 10.1177/000331979304400704, 8328680.
3. Yoshimuta T, Akutsu K, Okajima T, Tamori Y, Kubota Y, Takeshita S. Corkscrew collaterals in Buerger's disease. Can J Cardiol 2009, 25:365. 10.1016/S0828-282X(09)70099-6, 2722480, 19536378.
4. Cooper LT, Henderson SS, Ballman KV, Offord KP, Tse TS, Holmes DR, Hurt RD. A prospective, case-control study of tobacco dependence in thromboangiitis obliterans (Buerger's Disease). Angiology 2006, 57:73-78. 10.1177/000331970605700110, 16444459.
5. Watts SW. Endothelin receptors: what's new and what do we need to know?. Am J Physiol Regul Integr Comp Physiol 2010, 298:R254-260. 10.1152/ajpregu.00584.2009, 2828166, 19907001.
6. Launay D, Diot E, Pasquier E, Mouthon L, Boullanger N, Fain O, Jego P, Carpentier P, Hatron PY, Hachulla E. Bosentan for treatment of active digital ulcers in patients with systemic sclerosis. Presse Med 2006, 35:587-592. 10.1016/S0755-4982(06)74645-0, 16614599.
7. Funauchi M, Kishimoto K, Shimazu H, Nagare Y, Hino S, Yano T, Kinoshita K. Effects of bosentan on the skin lesions: an observational study from a single center in Japan. Rheumatol Int 2009, 29:769-775. 10.1007/s00296-008-0789-z, 19037604.
8. Riccardi MT, Chialà A, lannone F, Grattagliano V, Covelli M, Lapadula G. Treatment of digital ulcers in systemic sclerosis with endothelin-1 receptor antagonist (bosentan). Reumatismo 2007, 59:135-139.
9. Tsifetaki N, Botzoris V, Alamanos Y, Argyriou E, Zioga A, Drosos AA. Bosentan for Digital Ulcers in Patients with Systemic Sclerosis: A Prospective 3-year Follow up Study. J Rheumatol 2009, 36:1550-1551. 10.3899/jrheum.080992, 19567637.
10. Shionoya S. Diagnostic criteria of Buerger's disease. Int J Cardiol 1998, 66(Suppl 1):S243-5.
11. Zimmerman NB. Occlusive vascular disorders of the upper extremity. Hand Clin 1993, 9(1):139-50.
12. Ouriel K. Noninvasive diagnosis of upper extremity vascular disease. Semin Vasc Surg 1998, 11(2):54-9.
13. Ruch D, Koman LA, Smith TL. Chronic vascular disorders of the upper extremity. J Am Society Surg Hand 2001, 1(1):73-80.
14. Maldonado FJ, Miralles J de H, Aguilar EM, Gonzalez AF, García JR, García FA. Relationship between noninvasively measured endothelial function and peripheral arterial disease. Angiology 2009, 60(6):725-731. 10.1177/0003319708327787, 19054793.
15. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007, 45(Suppl S):S5-67.
16. Ohta T, Ishioashi H, Hosaka M, Sugimoto I. Clinical and social consequences of Buerger Disease. J Vasc Surg 2004, 39:176-180. 10.1016/j.jvs.2003.08.006, 14718836.
17. Puéchal X, Fiessinger JN. Thromboangiitis obliterans or Buerger's disease:challenges for the rheumatologist. Rheumatology 2007, 46:192-199.
18. Todoli JA, Hernández MM, Arrébola MA. Efficacy of bosentan in digital ischemic ulcers. Ann Vasc Surg 2010, 24(5):690.e1-4.
19. De Haro J, Florez A, Fernandez JL, Acin F. Treatment of Buerger disease (thromboangiitis obliterans) with bosentan: a case report. BMJ Case Reports 2009, doi:10.1136/bcr.08.2008.0691. Published online: May 12th 2009. [http://casereports.bmj.com/content/2009/bcr.08.2008.0691].
20. Fiessinger JN, Schäfer M. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study. Lancet 1990, 335:555-557. 10.1016/0140-6736(90)90346-7, 1689791.
21. The European TAO Study Group Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): A double-blind, randomized, placebo-controlled trial. Eur J Vasc Endovasc Surg 1998, 15:300-307. The European TAO Study Group.
22. Szuba A, Cooke JR. Thromboangiitis Obliterans. An Update on Buerger's Disease. West J Med 1998, 168:255-260. 1304949, 9584663.
23. Makita S, Nakamura M, Murakami H, Komoda K, Kawazoe K, Hiramori K. Impaired endothelium-dependent vasorelaxation in peripheral vasculature of patients with thromboangiitis obliterans (Buerger's disease). Circulation 1996, 94(9 Suppl 2):211-215.
24. Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P, Stefanadis C, Mavrikakis M. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 2007, 56:1985-1993. 10.1002/art.22634, 17530638.
25. Czarnacki M, Gacka M, Adamiec R. A role of endothelin 1 in the pathogenesis of thromboangiitis obliterans (initital news). Przegl Lek 2004, 61(12):1346-50.